Cambium Bio has secured FDA confirmation that a single pivotal Phase 3 trial plus confirmatory evidence will suffice for Biologics License Application submission for Elate Ocular, significantly reducing development expenses and accelerating the pathway to market.
- FDA endorses single pivotal Phase 3 trial for Elate Ocular BLA
- Development costs and enrolment timelines substantially reduced
- Phase 3 study design remains unchanged with 400 evaluable patients
- Fast Track Designation enables rolling BLA submission
- Confirmatory evidence requirements to be defined post-trial readout
FDA Shifts Regulatory Paradigm for Elate Ocular
Cambium Bio (ASX:CMB) has won a significant regulatory nod from the US Food and Drug Administration, which confirmed that a single pivotal Phase 3 trial, supplemented by confirmatory evidence, will be sufficient to support a Biologics License Application (BLA) for its lead dry eye disease treatment, Elate Ocular®. This marks a departure from the traditional FDA requirement of two independent pivotal trials, aligning with the agency’s recent policy shift outlined by Dr Vinay Prasad and Dr Martin Makary earlier this year.
The FDA’s Type D meeting on 22 April 2026 crystallised this new pathway, giving Cambium Bio the green light to proceed with one adequately powered, well-controlled Phase 3 study, CAMOMILE-3, as the cornerstone for regulatory approval. This confirmation not only slashes the clinical development budget but also streamlines patient recruitment and site management into a single trial, expected to accelerate enrolment and reduce operational complexity.
Phase 3 Design and Fast Track Benefits Confirmed
The FDA reaffirmed the acceptability of Cambium Bio’s previously agreed Phase 3 study design: a randomised, double-masked, vehicle-controlled trial with 400 evaluable patients, co-primary endpoints measuring both signs and symptoms of dry eye disease, and a nine-week masked treatment period. This design remains intact under the single-trial framework, providing continuity and clarity for the company’s clinical operations.
Elate Ocular’s Fast Track Designation, granted in December 2024, permits rolling submission of the BLA, allowing Cambium Bio to submit sections of its application as data becomes available. This regulatory flexibility could further compress the timeline to potential approval, a welcome advantage given the substantial unmet need in moderate-to-severe dry eye disease.
Financial and Strategic Implications for Cambium Bio
By consolidating the pivotal trial requirement, Cambium Bio anticipates a meaningful reduction in clinical development capital outlay, though exact savings will depend on final operational parameters. This follows a recent string of funding boosts, including a $2.4 million strategic placement from a major shareholder earlier this year, which helped set the stage for Phase 3 patient dosing and manufacturing preparations across multiple regions.
The single-trial pathway also improves the statistical odds of regulatory success. Historically, demonstrating significance in two separate pivotal studies imposed a higher hurdle. Now, Cambium Bio can focus resources on generating robust data from one well-powered study, supported by confirmatory evidence that will be tailored post-readout in consultation with the FDA.
These developments build on the company’s recent progress securing global partnerships and fresh funding to advance its ophthalmology pipeline, as detailed in its February update on Phase 3 trials with strategic deals. The FDA’s regulatory clarity now provides Cambium Bio with a sharper operational focus: initiating the pivotal trial with First Patient In expected later this year and driving towards topline results and submission.
Confirmatory Evidence and Next Steps
The FDA emphasised that the scope of confirmatory evidence will be determined after the Phase 3 readout, allowing Cambium Bio to calibrate its supplementary data package based on the strength of clinical outcomes. Potential confirmatory evidence could include mechanistic studies, animal models, real-world data, or additional nonclinical characterisation, all aimed at reinforcing Elate Ocular’s mechanism of action.
CEO Karolis Rosickas welcomed the FDA’s pragmatic approach, highlighting the accelerated timeline and reduced capital intensity as key benefits for bringing a new treatment to the tens of millions affected by moderate-to-severe dry eye disease. With regulatory and operational uncertainties narrowing, Cambium Bio’s next milestones will be closely watched by investors and the ophthalmology biotech sector alike.
Bottom Line?
Cambium Bio’s streamlined FDA pathway for Elate Ocular cuts costs and time but hinges on successful Phase 3 outcomes and subsequent confirmatory evidence negotiations.
Questions in the middle?
- What specific confirmatory evidence will the FDA require following Phase 3 results?
- How quickly can Cambium Bio initiate and enrol patients in the pivotal trial given operational constraints?
- Will the single-trial approach influence regulatory strategies for other ophthalmology candidates?